Takeda

Início / Takeda

Categoria:

Janeiro 22, 2024

Associados | Takeda

U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

– HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only up to Once...

Novembro 15, 2023

Associados | Takeda

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

P-BIO October 15, 2023 - cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening...

Novembro 15, 2023

Associados | Takeda

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

P-BIOOctober 15, 2023- FRUZAQLA is the First Targeted Therapy Approved for Metastatic Colorectal Cancer (mCRC)...

A P-BIO é uma associação privada sem fins lucrativos que congrega empresas ligadas ao setor da Biotecnologia e Ciências da Vida em Portugal

Explore

Contacto

Telefone

(+351) 231410960

Email

sec.geral@p-bio.org

A nossa sede

Biocant Park
Parque Tecnológico de Cantanhede, Núcleo 04, Lote 02
3060-197 Cantanhede

Newsletter

Fique por dentro das últimas novidades

© Todos os direitos reservados